3E Bioventures Capital
Venture capitalPalo Alto · Seed–Series A · 5 people tracked
Find your way into 3E Bioventures Capital
2,296 people in our graph share verified history with the 3E Bioventures Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
3E Bioventures Capital backs global leading health innovators, focusing on biotech—including new drugs, new modalities, and drug discovery platforms—and TechBio, where biology intersects with technology to disrupt established paradigms. The firm follows a science-driven, entrepreneur-friendly philosophy, collaborating closely with companies and research institutions to develop drugs and products that address significant unmet medical needs. Its name reflects its guiding principles of Expertise, Efficiency, and Execution.
Source: firm website, verified Aug 3, 2026.
Team · 5 people
from public directories
What they invest in
from 33 of 50 portfolio companiesBiotech ×25Healthtech ×18Medical Devices ×16Deep Tech ×12AI & Machine Learning ×10Digital Health ×6Hardware ×4Advanced Manufacturing ×2
HQs:United States×22China×4Australia×1
Who they back
founder profiles across 19 portfolio companiesFounding team size:solo founder×52 founders×83 founders×34+ founders×3
Where their founders studiedfrom 12 founders with education data
Yale University ×2
What their founders studiedfrom 12 founders with field-of-study data
Engineering ×6Life Sciences ×4Medicine ×3Chemistry ×2
Where their founders worked beforefrom 12 founders with career history
Children's National Health System ×2Stanford University ×2University of Michigan ×2
Investments · 50 tracked
founders shown can be your intro pathBy year:2024 · 12022 · 42021 · 22020 · 32019 · 22017 · 12015 · 114 dated
C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.
BiotechCambridge, US
Kenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in
BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)
Co-investorsBain Capital Life SciencesNextech InvestRA CapitalCobro Ventures
Cytek Biosciences develops high-parametric analytical instruments and software that enable scientists at pharmaceutical companies, contract research organizations, and academic institutions to generate and analyze biological datasets.
BiotechDeep TechHardwareHealthtechMedical DevicesBellevue, US
Wenbin Jiang, Ph.D.(CEO and Chairman of the Board)Wenbin Jiang(Executive Officer, Director)inMing Yan, Ph.D.(Chief Technology Officer)Ming Yan(Executive Officer, Director)inJiecheng Zhang(Director)Allen Poirson(Director)
Co-investorsF-Prime CapitalNorthern Light Venture CapitalRA Capital
Profusa develops injectable hydrogel biosensors and AI-driven health platforms that enable real-time measurement of body chemistry from within tissue.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSan Francisco, US
Bill Fawcett(Co-founder)Natalie Wisniewski(Executive Officer, Director)inBen Healy(CEO)Ben Hwang(Executive Officer, Director)in
BoardQianye Karen Liu(Director)Thomas Gutshall(Director)
Co-investorsAsset Management CompanyAtinum Investment Co. Ltd.Sand Hill AngelsBioVentures
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)inEmily M. Leproust(Chief Executive Officer and Chair of the Board)inPatrick Finn(President and Chief Operating Officer)inAdam Laponis(Chief Financial Officer)in
Co-investors+ND CapitalARCH Venture PartnersAsset Management CompanyBay City CapitalBlack Opal VenturesDentsu Ventures+8 more
Arnatar develops a next-generation RNA discovery platform called DARGER that combines gene silencing and gene upregulation technologies for oligonucleotide therapeutics.
AI & Machine LearningBiotechDeep Tech
Dr. Xuehai Liang(Founder)Dr. Yanfeng Wang(Founder & Chief Operating Officer)
Co-investorsF-Prime CapitalApricot CapitalEight Roads VenturesGaorong VenturesLegend StarNew Alliance Capital
Dermaliq Therapeutics is a specialty pharmaceutical company developing topical dermatology therapies and medical skin care products based on its proprietary hyliQ drug-delivery platform, with a lead pipeline focused on hair loss conditions such as androgenetic alopecia and alopecia areata.
BiotechHealthtechWilmington, US
Oliver Schlüter(CFO & Co-Founder)Betsy Hughes-Formella(CSO & Co-Founder / R&D Consultant)Christian Roesky(CEO & President)
ProNovo Therapeutics is a biotechnology company developing precision small-molecule therapeutics for neuropsychiatric disorders, including Major Depressive Disorder and Schizophrenia.
BiotechHealthtechMental Health
Guang Chen(Founder, Board Director & Chief Scientific Officer)inXiaohu Deng(Co-Founder & CEO)inScott Thompson(Co-Founder & Chair of Scientific Advisory Board)in
Co-investorsGaorong Ventures
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
Co-investorsLAVLilly Asia VenturesQuan Capital3H Health InvestmentSherpa Healthcare PartnersYuanBio Venture Capital
BiotechHouston, US
Amato Giaccia(Director)Rudy Howard(Chief Financial Officer)Robert B. Geller(Chief Medical Officer)inGail McIntyre(Chief Executive Officer)Leonard Scott Dove(Chief Operating Officer)Joshua Brumm(Executive Officer)
Co-investorsAdvent Life SciencesEshelman Ventures, LLC
Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases.
BiotechDeep TechMedical DevicesHayward, US
Haifeng Chen(Director and Treasurer of the Issuer)inShengjiang Liu(Executive Officer, Director)
BoardYu Fang(Director of the Issuer)Qianye Karen Liu(Director of the Issuer)Nancy Chang(Director of the Issuer)
Co-investorsBioVentures
Cognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers.
BiotechHealthtechPittsburgh, US
Susan Catalano(Executive Officer, Director)inSusan Catalano, Ph.D.(Co-founder)Lisa Ricciardi(Chief Executive Officer)inHarold Safferstein(Executive Officer, Director)
BoardNada Jain(Director)Franz Hefti(Director)
Co-investorsAtlanta Technology AngelsHouston Angel NetworkiNetworksDolby Family VenturesGolden Seeds
Cullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach.
BiotechDeep TechHealthtechMedical Devices
Ying Luo(CEO)in
Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.
CleantechClimate TechDeep TechNew Materials
Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in
Co-investorsPacific ChannelARCH Venture PartnersEcoR1 CapitalGeneral CatalystLeaps by BayerMaverick Ventures+2 more
.png)
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)Anthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inAmeet Nathwani, M.D.(Executive Officer, Director)in
Co-investorsARCH Venture PartnersEcoR1 CapitalSamsara BioCapital6 Dimensions CapitalGeneral CatalystInnovation Endeavors+5 more
Eaglenos develops smart healthcare technologies, focusing on precision testing and personalized health management.
Digital HealthHealthtechMedical DevicesNanjing, CN
Epimab Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of bispecific antibodies using proprietary technology platforms including FIT-Ig® and MAT-Fab.
BiotechHealthtechMedical DevicesShanghai, CN
Wu Chenbing(Founder/Expert)
Co-investorsDecheng CapitalShangBay Capital LLCTCG LabsSherpa Healthcare Partners
FA International provides technology and business development advisory services for industrial and medical device companies, helping them evaluate pre- and post-investment opportunities and technology risks to optimize returns and develop growth strategies.
Advanced ManufacturingDeep TechEnterprise SoftwareHardwareMedical Devices
Galaxy Brain Scientific develops personalized brain mapping and neuromodulation technologies for research and clinical applications across neurological conditions.
AI & Machine LearningBiotechDeep TechMedical Devices
Genotix Bio develops the DaVinci, a compact nanoarray analyzer that detects proteins and nucleic acids at single-molecule resolution for research applications.
BiotechDeep TechDigital HealthHealthtechMedical DevicesSan Francisco, US
Dr. Yong Chen(Co-founder)George Brittain(Co-founder)inPan MaoinPhilippe Goix(CEO and Board Member)in
Lipidio Pharma is a drug development company that acquires molecules with unrealized therapeutic potential and advances them through preclinical and clinical development toward approval or exit.
BiotechHealthtechSan Diego, US
James Mackay(Co-Founder)David Bullough(Director)Daniel Petree(Director)J. Gordon Foulkes(Executive Officer, Director)
LumiThera develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation (PBM) device that applies multiple light wavelengths to treat early and intermediate dry age-related macular degeneration (AMD).
BiotechHealthtechMedical DevicesPoulsbo, US
Tracy Puckett(Executive Officer)Clark Tedford(Executive Officer, Director)inScott Bradley(Executive Officer)inDuane Morrison(Executive Officer)inCindy Croissant(Executive Officer)Ryan Montecucco(Executive Officer)
Co-investorsLife Sciences Greenhouse InvestmentsImagine VenturesKeiretsu Capital
Mediaspace is a digital agency that designs and builds custom Squarespace websites and provides SEO, digital marketing strategy, and digital advertising services.
AdTechAdvanced ManufacturingAI & Machine LearningData & InfrastructureDigital HealthEnterprise SoftwareHardwareHealthtechMarketing TechMedical DevicesSemiconductorsAtlanta, US
John G. Edwards(Executive Officer, Director)John Jacobi(Executive Officer)Sri Peruvemba(Executive Officer)Francois Jeanneau(Executive Officer, Director)Linda Ara(Executive Officer)Michael Vestel(Executive Officer)
Co-investorsKeiretsu ForumLife Sciences Greenhouse InvestmentsToba CapitalVivo Capital
Myrobalan Therapeutics is a pre-clinical biotech company developing small molecule therapies targeting microglia and oligodendrocytes to address neurodegeneration and demyelinating disorders.
AI & Machine LearningBiotechDeep TechMedical DevicesBoston, US
Jing Wang, PhD(Co-Founder & CEO)Guoping Feng, PhD(Scientific Co-Founder)Zhigang He(Scientific Co-founder)Guoping Feng(Scientific Co-founder)
OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders.
BiotechHealthtechRockville, US
Yang Liu(Co-founder)inPan Zheng(Co-founder)inMartin Devenport(Executive Officer)Michael Flaschen(Director)
Co-investorsHM Venture Partners
First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.
BiotechRockville, US
Pan Zheng(Executive Officer)Yang Liu(Executive Officer, Director)Martin Devenport(Executive Officer)
BoardMiao Hong(Director)Karen Liu(Director)inKun-Liang Guan(Director)
Co-investorsHM Venture Partners
Quadriga BioSciences is an oncology startup developing targeted small molecule chemotherapeutics for cancer treatment, with a focus on central nervous system malignancies and immune-mediated disorders.
BiotechHealthtechMedical Devices
Gordon Ringold(CEO)Bernd Jandeleit(Co-Founder)Wolf-Nicolas Fischer(Co-Founder)Kerry J. Koller(Co-Founder)
Rapafusyn develops molecular glue therapeutics using its RapaGlue platform of non-degrading macrocyclic compounds designed to modulate hard-to-drug intracellular and transmembrane protein targets.
AI & Machine LearningBiotechDeep TechBaltimore, US
Jun O. Liu(Founder)
Co-investorsBioTrack Capital
Shanton Pharma is a clinical-stage biotech company developing drugs for gout, hyperuricemia, and pruritus.
BiotechHealthtech
Smartlens develops wearable microfluidic devices and AI-powered platforms for remote monitoring and diagnosis of anterior segment eye diseases, particularly glaucoma.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Savas Komban(Founder)in
Co-investorsAmbit Health VenturesStanford University
Subtle Computing (legally Skywalk, Inc.) makes wireless earbuds sold directly at subtle.co and through authorized resellers, along with a companion mobile app.
AI & Machine LearningConsumerDirect to ConsumerHardware
Tyler Chen(Founder)in
Co-investorsAbstract VenturesEntrada VenturesInception Studio CapitalSLVCBaidu VenturesBessemer Venture Partners+10 more
Subtle Medical develops deep learning software for medical imaging that enables faster and safer image acquisition on existing scanners for healthcare providers and imaging centers.
AI & Machine LearningHealthtechMedical Devices
Greg Zaharchuk(Co-founder, MD, Ph.D., Neuroradiologist and Professor at Stanford)inEnhao Gong(Co-founder, Ph.D., Deep Learning Scientist)in
Co-investorsAtinum Investment Co. Ltd.Bessemer Venture PartnersBreyer CapitalDCVC (Data Collective)Foothill VenturesFusion+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ApexigenArnatarCytekEluminexEluminexbioGenotixLarkspurLipidioLysowayLysoway TherapeuticsMyro TherapeuticsMyrobalan TherapeuticsNanoInsights-TechNeural GalaxyProNovoRegenacy PharmaceuticalsRetex PharmaceuticalsSHANTONTwist
Exits · 4
4 IPOsC4 TherapeuticsNASDAQ: CCCCCytek BiosciencesNASDAQ: CTKBProfusaNASDAQ: PFSATwist BioscienceNASDAQ: TWST
Portfolio news
latest coverage across their companiesCognition Therapeutics · manilatimes.net · Sep 8, 2026
Rapafusyn · prnewswire.com · Sep 2, 2026
Arnatar Therapeutics · dakota.com · Aug 18, 2026
C4 Therapeutics · stocktitan.net · Aug 14, 2026
Alebund · fiercebiotech.com · Aug 12, 2026
Profusa · investing.com · Jun 10, 2026
Subtle · pulse2.com · Jun 3, 2026
Frequently asked questions
- How many investments has 3E Bioventures Capital made?
- 3E Bioventures Capital has 50 tracked investments, 4 of which have exited.
- What stage does 3E Bioventures Capital invest at?
- 3E Bioventures Capital invests at the Seed, Series A stages.
- What sectors does 3E Bioventures Capital focus on?
- 3E Bioventures Capital focuses on AI & Machine Learning, Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is 3E Bioventures Capital located?
- 3E Bioventures Capital is headquartered in Palo Alto, US.
- Does 3E Bioventures Capital lead rounds?
- 3E Bioventures Capital typically participates in rounds rather than leading them.
- Who does 3E Bioventures Capital co-invest with?
- 3E Bioventures Capital most often shares deals with ARCH Venture Partners, Asset Management Company, F-Prime Capital, among 39 tracked co-investors.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.